Researchers investigating childhood leukaemia have discovered that increasing MLL gene expression in iPSCs drives hematopoietic stem cell production, so could be the target of new therapies. Researchers have identified that increasing the expression of the normal form of the MLL gene can drive production of hematopoietic stem cells (HSCs). This not only provides a protocol
First study to evaluate de-identified data from wearable devices on resting heart rate and sleep finds improved real-time prediction of influenza-like illness in 5 US states compared to current surveillance methods The research, published in The Lancet Digital Health journal, demonstrates the potential of data from wearable devices to improve surveillance of infectious disease. Resting heart rate
The method melds the best of super-resolution fluorescence and electron microscopy to show how proteins relate to cells’ fine structure. Inside a cell, tentacled vesicles shuttle cargo for sorting. Neighboring neurons cling to one another through a web-like interface. DNA rearranges in the nucleus as stem cells differentiate into neurons. And a new microscopy technique
Cancer patients responded better to immunotherapy and had a better prognosis if their melanoma tumours contained specific clusters of B cells, according to new research from Lund University in Sweden. The study is published in Nature. Source Lund University Immunotherapy strengthens the immune system so that it can fight cancer more effectively. One type of
Source World Economic Forum The current market for stem cell therapies is growing at 36% per year and will rapidly expand when a breakthrough treatment for non-communicable disease or a lifestyle factor occurs. Funding is flowing into the sector from venture capitalists and large companies. With greater resources and an increasingly experienced talent pool, scientists
A new study from Washington University School of Medicine in St. Louis suggests that bone marrow — or blood stem cells — from healthy donors can harbor extremely rare mutations that can cause health problems for the cancer patients who receive them. Such stem cell transplants are important for treating blood cancers, including acute myeloid
The UK and the NHS are providing the right environment and infrastructure to allow innovative cell and gene therapies to reach patients. International companies recognise the appeal of the UK cell and gene therapy ecosystem and are sponsoring the majority of the UK commercial clinical trials which account for 77% of the total 127 ongoing trials.
First agreements with statutory health insurances utilize bluebird’s innovative value-based payment model and provide coverage for ZYNTEGLO for up to 50% of patients in Germany First qualified treatment center established at University Hospital of Heidelberg to provide ZYNTEGLO to patients bluebird bio, Inc. announced the launch in Germany of ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene), a
ARM today announced the release of a report, “A Transformative Therapy Value Model for Rare Blood Diseases.” The report uses a refined value model to assess the impact of durable and potentially curative cell and gene therapies on health system costs. Produced in collaboration with the Marwood Institute, this report calculates the potential cost savings that
Computational biologists led by Prof. Yvan Saeys (VIB-UGent Center for Inflammation Research) developed a new bioinformatics method to better study communication between cells. This method, called NicheNet, helps researchers to gain insight into how the gene expression of cells is regulated by interacting cells. NicheNet has a broad range of potential applications in fields like
